Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. - Wikidata - wikimedia - TriplyDB

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

http://www.wikidata.org/entity/Q42508698

about

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine Supervised risk predictor of breast cancer based on intrinsic subtypes Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.Structural similarity assessment for drug sensitivity prediction in cancer.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer.Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer.Optical fiber-based in vivo quantification of growth factor receptors.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.Primary trastuzumab resistance: new tricks for an old drug.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.Invasive Breast Cancer: Recognition of Molecular Subtypes Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.Genetic characterization of breast cancer and implications for clinical management Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.Resistance to Trastuzumab in Breast Cancer.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

P2860

Q24313194-2593BFC8-E64B-4A14-8432-155447E1351B Q26743510-A78C65F8-AD9A-4B44-9B6F-4BA5E9BE12CB Q28084565-D5E2114D-19E6-4247-8739-1F8138C0A7C9 Q28554790-37D94237-DEFC-4812-B535-88B1AB4AE801 Q29617404-A5FF2F3A-0792-4C03-9D75-AAE2F2309921 Q29617584-D7BC1F02-856B-45E2-BC78-55A61E22BAB9 Q33459037-07C91E65-0FFC-434F-8169-31070113A123 Q33504374-84413C89-7B3A-43D7-979A-A5DE7B6BC9E7 Q33601653-1753E8B5-FAB1-4F47-AC3F-89BDA5CF70E1 Q33712476-B375A338-CEE4-4773-9941-60AA812446F3 Q33735413-2F5CD169-F1A2-4EA6-90AD-81B0F7EB7A98 Q33745113-BEFF10A5-F4B4-436C-B5A3-B78A187F770A Q33816178-6C3B5758-831F-4DEE-A76C-A4E2E8E1B55B Q33951586-3E690E85-D0CD-46B3-9048-BCB35C18441F Q34117974-C6FB39BE-19A7-4AE1-93F9-3C1EC2EACEB0 Q34226408-88D620B1-467C-4D1E-84DF-55267E403666 Q34355748-D7F93E3B-D784-4A31-B02D-4D66F3647EF4 Q34512811-7BD4230B-2A1F-422C-B144-F422F9AB6BFC Q34610251-08655708-5517-47B1-8BCC-E2B61361238E Q34615545-193E8789-329A-4F84-A830-F0C54C90B181 Q34664129-5261CD02-CE19-4686-A33B-A08A77F873D9 Q34694211-58062DA2-3CE5-43E1-AF55-B2A76136F3E5 Q34946846-EEF757CC-867C-447D-B8FA-D7CECD7D383C Q35005626-97766B66-97B4-4091-8636-52415EE93BCA Q35100621-8754DBD7-2CC3-4995-A2BF-86C1B6B92044 Q35535296-79C251D3-017B-4FA7-8CBF-E4834F22F3BB Q35546950-991FD164-620D-4C94-A235-B9D1789B212D Q35576242-B6FC6942-E728-4B2B-AA74-FAFE874EE102 Q35740160-7D4F35AF-BA26-4D15-8F63-D7C730B99E0A Q35742760-702D42A5-4855-4881-A170-CF1A046C4B1B Q35803226-05B337F0-C8C6-43FE-A649-D90BB5AB245E Q35808400-63AF228C-A009-4119-A565-8EC42700FB29 Q35832016-5E89A997-E47B-428E-B506-9C62A3D6A61E Q35889941-8D86941E-2E3A-46F5-9DB3-3AF564645001 Q36088788-59502315-12BF-46A1-9A94-D24C59B8C2F4 Q36098453-16608DB9-3178-400E-BBF7-7EC2A3491298 Q36102124-F5C32202-9025-43ED-B38C-6732D29675B1 Q36279794-D0F38010-5CF2-4620-B23A-827C85F236FC Q36318226-1BCED567-DF75-44F6-99A7-DF6006747102 Q36440214-DDA80D7D-F918-472B-B983-DAFD7E6C77A4

P2860

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

http://www.wikidata.org/entity/Q42508698

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Predictors of resistance to pr ...... -positive early breast cancer.

@en

Predictors of resistance to pr ...... -positive early breast cancer.

@nl

type

label

Predictors of resistance to pr ...... -positive early breast cancer.

@en

Predictors of resistance to pr ...... -positive early breast cancer.

@nl

prefLabel

Predictors of resistance to pr ...... -positive early breast cancer.

@en

Predictors of resistance to pr ...... -positive early breast cancer.

@nl

P1433

Q42508698-AA2B2BEF-4038-4395-B141-D823EF7046E0

P1476

Q42508698-CE37732D-5F4A-4885-B2FE-ACD23F628D9E

P2093

Q42508698-1710BECC-CFBE-49B9-8151-565ECDA7C449

Q42508698-253517C7-39B6-42FB-8DB1-20A8BD9DC79E

Q42508698-3F20477F-82FA-4EEF-8B8D-C62CC9C1F11E

Q42508698-4B104166-4421-440F-A47A-EDFD9043FDF3

Q42508698-5A405D61-8999-451F-AE09-9A99D5A80D9D

Q42508698-5B044A8F-AAED-453B-B7C9-CBC11A80C43B

Q42508698-5FBF5616-9C2D-47CF-98E2-525EB3BDCB91

Q42508698-6E2C3E3F-2BEC-4CB1-A2E9-A07BAC9C9A2A

Q42508698-8AEA7CCB-89AE-4FE7-B781-8A94210CD67C

Q42508698-AF15841D-D240-458B-9E14-32A4FEDEBF7D

P304

Q42508698-10D7987C-88D0-473B-984D-0FFDC1D45DE0

P31

Q42508698-A25DFAFA-8091-4AB2-BAD4-568D5225D837

P356

Q42508698-CE6767F9-131C-492F-B72A-9CE30646FFDF

P407

Q42508698-33090055-090F-49CB-AA06-EA02A4814B13

P433

Q42508698-D7CDF43F-D4C9-4A6C-89C3-687C2392CF9F

P478

Q42508698-CA673FA8-C9DC-4127-B3C1-A862226FA031

P577

Q42508698-1CC431E3-C950-4D46-9C29-5396F650B43D

P698

Q42508698-9440E50C-335A-429D-BC40-1127E8E9E5DD

P356

1078-0432.CCR-06-1304

P1433

Clinical Cancer Research

P1476

Predictors of resistance to pr ...... -positive early breast cancer.

@en

P2093

Agnes Witkiewicz

http://www.w3.org/2001/XMLSchema#string

Beth-Ann Lesnikoski

http://www.w3.org/2001/XMLSchema#string

Dennis Sgroi

http://www.w3.org/2001/XMLSchema#string

Eric P Winer

http://www.w3.org/2001/XMLSchema#string

Fanglei You

http://www.w3.org/2001/XMLSchema#string

Harold J Burstein

http://www.w3.org/2001/XMLSchema#string

J Dirk Iglehart

http://www.w3.org/2001/XMLSchema#string

Lyndsay N Harris

http://www.w3.org/2001/XMLSchema#string

Madhavi Kamma

http://www.w3.org/2001/XMLSchema#string

Paula D Ryan

http://www.w3.org/2001/XMLSchema#string

P304

1198-1207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-1304

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17317830

http://www.w3.org/2001/XMLSchema#string